

Table 9.27
All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2004-2010

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
Lymphoid Neoplasm	76,239	68.6 (68.2 , 69.1)	90.0 (88.9 , 91.0)	78.6 (78.1 , 79.1)	57.7 (56.9 , 58.4)			
1 Hodgkin Lymphoma	6,826	86.4 (85.4 , 87.3)	96.0 (94.2 , 97.2)	91.5 (90.5 , 92.4)	52.7 (48.6 , 56.6)			
1(a) Classical Hodgkin lymphoma	6,610	86.1 (85.1 , 87.1)	95.9 (94.0 , 97.1)	91.3 (90.3 , 92.2)	51.6 (47.5 , 55.5)			
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	897	77.0 (73.4 , 80.2)	94.9 (84.7 , 98.4)	86.3 (82.6 , 89.3)	55.6 (47.8 , 62.8)			
1(a)1.1 Lymphocyte-rich	186	85.2 (76.4 , 90.9)	- (- , -)	90.2 (80.8 , 95.2)	70.1 (49.6 , 83.5)			
1(a)1.2 Mixed cellularity	633	76.8 (72.5 , 80.5)	93.2 (80.0 , 97.8)	85.7 (81.3 , 89.2)	56.2 (46.9 , 64.5)			
1(a)1.3 Lymphocyte-depleted	78	56.7 (42.8 , 68.4)	- (- , -)	75.1 (55.8 , 86.8)	27.1 (10.8 , 46.4)			
1(a)2. Nodular sclerosis	4,402	90.5 (89.4 , 91.5)	95.8 (93.7 , 97.2)	93.3 (92.2 , 94.3)	54.9 (48.5 , 60.9)			
1(a)3. Classical Hodgkin lymphoma, NOS ^c	1,311	76.9 (74.1 , 79.5)	97.2 (91.4 , 99.1)	86.7 (83.8 , 89.1)	42.9 (35.8 , 49.8)			
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	216	95.2 (88.4 , 98.1)	100.0 (- , -)	96.2 (89.7 , 98.6)	78.1 (29.0 , 95.2)			
2 Non-Hodgkin lymphoma	67,208	67.4 (66.9 , 67.9)	88.1 (86.7 , 89.3)	76.6 (76.0 , 77.2)	58.5 (57.7 , 59.2)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	38	46.4 (25.6 , 64.8)	- (- , -)	- (- , -)	- (- , -)			
4 Lymphoid neoplasm, NOS ^c	2,167	48.3 (45.5 , 51.0)	86.8 (64.3 , 95.6)	65.1 (60.8 , 69.2)	39.7 (36.3 , 43.1)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified.

- Statistic not displayed due to less than 25 cases.